Pfizer Inc
NYSE:PFE
Intrinsic Value
Pfizer Inc. is a research-based global biopharmaceutical company. [ Read More ]
The intrinsic value of one PFE stock under the Base Case scenario is 21.972 USD. Compared to the current market price of 25.355 USD, Pfizer Inc is Overvalued by 13%.
Valuation Backtest
Pfizer Inc
Run backtest to discover the historical profit from buying and selling PFE stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Pfizer Inc
Current Assets | 43.3B |
Cash & Short-Term Investments | 12.7B |
Receivables | 15.2B |
Other Current Assets | 15.5B |
Non-Current Assets | 183.2B |
Long-Term Investments | 15.4B |
PP&E | 18.9B |
Intangibles | 132.7B |
Other Non-Current Assets | 16.2B |
Current Liabilities | 47.8B |
Accounts Payable | 6.7B |
Accrued Liabilities | 2.8B |
Short-Term Debt | 8.1B |
Other Current Liabilities | 30.2B |
Non-Current Liabilities | 89.7B |
Long-Term Debt | 61.5B |
Other Non-Current Liabilities | 28.2B |
Earnings Waterfall
Pfizer Inc
Revenue
|
58.5B
USD
|
Cost of Revenue
|
-17.8B
USD
|
Gross Profit
|
40.7B
USD
|
Operating Expenses
|
-27.6B
USD
|
Operating Income
|
13.1B
USD
|
Other Expenses
|
-11B
USD
|
Net Income
|
2.1B
USD
|
Free Cash Flow Analysis
Pfizer Inc
PFE Profitability Score
Profitability Due Diligence
Pfizer Inc's profitability score is 63/100. The higher the profitability score, the more profitable the company is.
Score
Pfizer Inc's profitability score is 63/100. The higher the profitability score, the more profitable the company is.
PFE Solvency Score
Solvency Due Diligence
Pfizer Inc's solvency score is 40/100. The higher the solvency score, the more solvent the company is.
Score
Pfizer Inc's solvency score is 40/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
PFE Price Targets Summary
Pfizer Inc
According to Wall Street analysts, the average 1-year price target for PFE is 31.722 USD with a low forecast of 26.26 USD and a high forecast of 47.25 USD.
Ownership
PFE Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
PFE Price
Pfizer Inc
Average Annual Return | 14.34% |
Standard Deviation of Annual Returns | 30.69% |
Max Drawdown | -57% |
Market Capitalization | 143.2B USD |
Shares Outstanding | 5 662 540 000 |
Percentage of Shares Shorted | 1.15% |
PFE News
Last Important Events
Pfizer Inc
Significant happenings or occurrences that are of interest to investors. These could be company-specific developments or market-wide shifts.
Sentiment Analysis
Pfizer Inc
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Pfizer Inc. is a research-based global biopharmaceutical company. The company is headquartered in New York City, New York and currently employs 79,000 full-time employees. The firm is engaged in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products. Its global portfolio includes medicines and vaccines. The firm offers therapeutic candidates in gastroenterology, dermatology, and cardiology, including etrasimod, an oral, selective sphingosine 1-phosphate (S1P) receptor modulator in development for a range of immuno-inflammatory diseases, including ulcerative colitis, Crohn’s Disease, atopic dermatitis, eosinophilic esophagitis, and alopecia areata. The firm works across markets to develop wellness, prevention, treatments and cures. The company collaborates with healthcare providers, governments and local communities to support and provide access to healthcare. The firm's medicines and vaccines provide value for healthcare providers and patients, through treatment of diseases, improvements in health, wellness.
Contact
IPO
Employees
Officers
The intrinsic value of one PFE stock under the Base Case scenario is 21.972 USD.
Compared to the current market price of 25.355 USD, Pfizer Inc is Overvalued by 13%.